Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: Case report and review of the literature

Heart and Lung: Journal of Acute and Critical Care

Volumn 41, Issue 5, 2012, Pages 512-517

  Mercurio, Valentina ^a   Carlomagno, Guido ^a   Fazio, Serafino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Pulmonary circulation; Pulmonary emphysema; Pulmonary fibrosis; Pulmonary hypertension; Sildenafil; Smoking

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOOP DIURETIC AGENT; SILDENAFIL; SITAXSENTAN; WARFARIN;

AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; DYSPNEA; EMPHYSEMA; EXERCISE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG VOLUME; MALE; OXYGEN THERAPY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SMOKING; THORAX RADIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

AGED; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, INTERSTITIAL; MALE; PIPERAZINES; PULMONARY CIRCULATION; PURINES; RADIOGRAPHY, THORACIC; RESPIRATORY FUNCTION TESTS; SMOKING; SULFONES; VASODILATOR AGENTS;

EID: 84865586160     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2011.09.005     Document Type: Article

References (19)

1. Cottin V., Cordier J.F. The syndrome of combined pulmonary fibrosis and emphysema. Chest 2009, 136:1-2.
2. Cottin V., Nunes H., Brillet P.Y., Delaval P., Devouassoux G., Tillie-Leblond I., et al. GERMOP: combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005, 26:586-593.
3. Aduen J.F., Zisman D.A., Mobin S.I., Venegas C., Alvarez F., Biewend M., et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc 2007, 82:48-54.
4. Kitaguchi Y., Fulimoto K., Hanaoka M., Kawakami S., Honda T., Kubo K. Clinical characteristics of combined pulmonary fibrosis and emphysema. Respirology 2010, 15:265-271.
5. Patel N.M., Lederer D.J., Borczuk A.C., Kawut S.M. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007, 132:998-1006.
6. Cottin V., Nunes H., Mouthon L., Gamondes D., Lazor R., Hachulla E., et al. GERMOP: combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011, 63:295-304.
7. Lucattelli M., Bartalesi B., Cavarra E., Fineschi S., Lunghi B., Martorana P.A., et al. Is neutrophil elastase the missing link between emphysema and fibrosis? Evidence from two mouse models. Respir Res 2005, 26:6-83.
8. Schiess R., Senn O., Fischler M., Huber L.C., Vatandaslar S., Speich R., et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010, 138:1086-1092.
9. De Cunto G., Cardini S., Cirino G., Geppetti P., Lungarella G., Lucattelli M. Pulmonary hypertension in smoking mice over-expressing protease-activated receptor-2. Eur Respir J 2011, 37:823-834.
10. Wei X.H., Wu X.Y., Wang J.H., Thakur A., Ma A.Q. Correlation of lymphocytes and PIIINP with the combined pulmonary fibrosis and emphysema. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2010, 26:675-678.
11. Mejía M., Carrillo G., Rojas-Serrano J., Estrada A., Suárez T., Alonso D., et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009, 136:10-15.
12. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group: sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
13. Ghofrani H.A., Wiedemann R., Rose F., Schermuly R.T., Olschewski H., Weissmann N., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 2002, 360:895-900.
14. Collard H.R., Anstrom K.J., Schwarz M.I., Zisman D.A. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007, 131:897-899.
15. Madden B.P., Allenby M., Loke T.K., Sheth A. A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. Vascul Pharmacol 2006, 44:372-376.
16. Zisman D.A., Schwarz M., Anstrom K.J., Collard H.R., Flaherty K.R., Hunninghake G.W. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010, 363:620-628.
17. Swigris J.J., Brown K.K. The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. Biodrugs 2010, 24:49-54.
18. King T.E., Behr J., Brown K.K., du Bois R.M., Lancaster L., de Andrade J.A., et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 177:75-81.
19. Barst R.J., Langleben D., Badesch D., Frost A., Lawrence E.C., Shapiro S., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006, 47:2049-2056.